{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:18:57Z","timestamp":1782861537929,"version":"3.54.5"},"reference-count":24,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To evaluate the long\u2010term safety and efficacy of vibegron 50\u00a0mg and 100\u00a0mg, a novel \u03b2\n                      <jats:sub>3<\/jats:sub>\n                      \u2010adrenoreceptor agonist, in Japanese patients with overactive bladder.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a 1\u2010year, multicenter, open\u2010label, non\u2010controlled study. After a 1\u2010week observation phase, patients were treated with vibegron for 52\u00a0weeks. When the efficacy was insufficient after an 8\u2010week treatment with 50\u00a0mg, the dose was increased to 100\u00a0mg and maintained for an additional 44\u00a0weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among a total of 169 patients receiving one or more doses of vibegron, 118 (69.8%) received vibegron 50\u00a0mg for 52\u00a0weeks, and the dose was increased to 100\u00a0mg in 51 (30.2%) patients. The incidence of drug\u2010related adverse events was 18.1% (21\/116) in the vibegron 50\u00a0mg group and 11.8% (6\/51) in the vibegron 100\u00a0mg group. Most frequent drug\u2010related adverse events were dry mouth (3.0%), residual urine volume increased (3.0%), constipation (2.4%) and cystitis (1.8%). Statistically significant changes in overactive bladder symptom variables (daily means of micturitions, urgency episodes, urgency incontinence episodes, incontinence episodes and night\u2010time frequency) from baseline were observed at week\u00a04 and maintained until week\u00a052. The condition of patients who did not respond well to vibegron 50\u00a0mg was much improved by increasing the dose to 100\u00a0mg. Vibegron improved the quality of life, and the proportion of patients\u2019 satisfaction after the treatment with vibegron was high.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long\u2010term (52\u2010week) treatment with vibegron is safe, well\u2010tolerated and effective in patients with overactive bladder.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/iju.13596","type":"journal-article","created":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T00:57:11Z","timestamp":1526086631000},"page":"668-675","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Long\u2010term safety and efficacy of the novel \u03b2\n                    <sub>3<\/sub>\n                    \u2010adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase\n                    <scp>III<\/scp>\n                    prospective study"],"prefix":"10.1111","volume":"25","author":[{"given":"Masaki","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Urology National Centre for Geriatrics and Gerontology Obu Aichi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Kakizaki","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University Asahikawa Hokkaido Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Urology Nihon University School of Medicine, Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nagai","sequence":"additional","affiliation":[{"name":"Kyorin Pharmaceutical Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kurose","sequence":"additional","affiliation":[{"name":"Kyorin Pharmaceutical Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05835.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00097-6"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1396257"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00622-7"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.08.017"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0000000000000207"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61994-3"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0022-3565(24)38094-2","article-title":"Evidence for beta3\u2010adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods","volume":"288","author":"Takeda M","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702358"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098616659412"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2014.823"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01372"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.237313"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10169"},{"key":"e_1_2_8_19_1","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","journal-title":"Psychiatry (Edgmont)."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07205.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12505"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-13"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02626.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000851"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2011.99"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.13596","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.13596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T09:16:17Z","timestamp":1751620577000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.13596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/iju.13596"],"URL":"https:\/\/doi.org\/10.1111\/iju.13596","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733222990.793577808","asserted-by":"object"}]},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]},"assertion":[{"value":"2017-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}